Comparison of biological and chemical assays for the quantitation of rifapentine in human plasma

Diagnostic Microbiology and Infectious Disease

Volumn 27, Issue 4, 1997, Pages 107-111

  Kenny, Michael T ^a,c   Reynolds, Donald L ^b   Brackman, Marcia A ^a   Dulworth, Jacqueline K ^a  

^a Microbiology Group   (United States)

^b Pharmacokinetics Department   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAPENTINE;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS SUBTILIS; BIOASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BACTERIOLOGICAL TECHNIQUES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MICROBIAL SENSITIVITY TESTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RIFAMPIN;

EID: 0030927136     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00027-8     Document Type: Article

References (25)

1. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R (1981) Antibacterial activity of DL-473, a new semisynthetic rifamycin derivative. J Antibiot 37:1026-1032.
2. Baohong J, Jiakun C, Xizhen L, Shiyu W, Guoxing N, Yuhong M, Daomai Z, Quankui T (1986) Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473. Int J Lepr 54:563-577.
3. Bermudez LE, Wu M, Young LS, Inderlied CB (1992) Post-antibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. J Infect Dis 166:923-926.
4. Birmingham AT, Coleman AJ, Orme MLE, Park BK, Pearson NJ, Short AH, Southgate PJ (1978) Antibacterial activity in serum and urine following oral administration in man of DL 473 ( a cyclopentyl derivative of rifampicin). Br J Clin Pharm 6:455P.
5. Brown ST, Edwards FF, Bernard EM, Tong W, Armstrong D (1993) Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobaderium avium complex in rats treated with cyclosporine. Antimicrob Agents Chemother 37:398-402.
6. Bruna CD, Olliaro P (1994) Setting breakpoints for assessing the sensitivity of mycobacteria to rifabutin in vitro. J Antimicrob Chemother 34:184-186.
7. Cricchio R, Arioli V, Lancini GC (1975) Hydrazones of 3-formyl rifamycin SV hydrazone with N-amino-N′-substituted piperazines: Synthesis, antibacterial activity, and other biological properties. IL Farmaco Ed Sci 30:605-619.
8. Cynamon MH (1985) Comparative in vitro activities of MDL 473, rifampin, and ansmycin against Mycobaderium intracellulame. Antimicrob Agents Chemother 28:440-441.
9. Dhillon J, Mitchison DA (1992) Activity in vitro of rifabutin, FCE 22807, rifapentine and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Resp Dis 145:212-214.
10. Dickinson JM, Mitchison DA (1987) In vitro activity of new rifamycins against rifampin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68:113-118.
11. Erickson RC, Hildebrand AR, Hoffman PF, Gibson CB (1989) A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics. Diagn Microbiol Infect Dis 12:235-241.
12. Fordham von Reyn C, Jacobs NJ, Arbeit RD, Maslow JN, Niemczyk S (1995) Polyclonal Mycobacterium avium infections in patients with AIDS: Variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient. J Clin Microbiol 33:1008-1010.
13. Heifets LB (1991a) Drug susceptibility tests and the clinical outcome of chemotherapy. In Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, Ed LB Heifets. Boca Raton, FL: CRC Press, pp. 1-11.
14. Heifets LB (1991b) Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellularae and other slowly growing nontuberculosis mycobacteria. In Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, Ed LB Heifets. Boca Raton, FL: CRC Press, pp. 123-146.
15. Heifets LB (1996) Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 40: 1759-1767.
16. eifets LB, Lindholm-Levy PJ, Flory MA (1990) Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am Rev Resp Dis 141:626-630.
17. Keung ACF, Miller TD, Green VI, Ames M, Eller MG, Weir SJ (1995) Bioavailability and food effect study of rifapentine in healthy adults. Pharm Res 12(suppl 9):S-8372.
18. Klemens SP, Cynamon MH (1991) In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 35:2026-2030.
19. Klemens SP, Grossi MA, Cynamon MH (1994) Comparative in vitro activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother 28:234-237.
20. Mor N, Simon B, Mezo N, Heifets L (1995) Comparison of activities of the rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chermother 39:2073-2077
21. National Committee for Clinical Laboratory Standards (NCCLS) (1994) Development of in vitro testing criteria and quality control parameters: Approved guideline M23-A. Villanova, PA: NCCLS.
22. Pascual A, Tsukayama D, Kovarik J, Gekker G, Peterson P (1987) Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur J Clin Microbiol 6:152-157.
23. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde IL, Pocilado JJ (1991) Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 35:1356-1359.
24. Wright EL, Quenelle DC, Suling WJ, Baaron WN (1996) Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob Agents Chemother 40:2206-2208.
25. Yates MD, Collins CH (1982) Comparison of the sensitivity of mycobacteria to cyclopentyl rifamycin DL 473 and rifampicin. J Antimicrob Chemother 10:147-150.